Hepatocellular Carcinoma Patient Outcomes with Portal Vein Thrombus, 2021-2024

478 patients newly diagnosed with hepatocellular carcinoma and portal vein tumor thrombus were analyzed between January 2021 and December 2024. The dataset, shared by figshare admin karger, compares survival outcomes for combined systemic and locoregional therapy versus systemic therapy alone. Results include median overall survival of 15.7 versus 5.9 months and progression-free survival of 7.0 versus 3.6 months for the respective treatment groups.

Use Cases

• Train survival prediction models based on overall survival and progression-free survival outcomes.
• Conduct propensity score matching analysis based on the described patient cohort and baseline characteristics.
• Analyze treatment response rates based on the reported disease control rate (DCR) metric.
• Investigate subgroup treatment effects based on variables like Vp4 PVTT type and Child-Pugh liver function score.

Strengths

• Includes data for 478 patients with a defined diagnosis and time range (2021-2024).
• Provides specific clinical outcome metrics: median OS (15.7 vs. 5.9 months), median PFS (7.0 vs. 3.6 months), and DCR (43.5% vs. 27.5%).
• Analysis uses a recognized statistical method (propensity score matching) to balance patient groups.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying raw data is unknown, which may limit suitability assessment.
• Data is stored in a DOCX file (24.0 KB), suggesting a small, likely summary-level dataset rather than raw patient records.

Provenance

Source

figshare admin karger

Collection Method

Retrospective analysis of patient records.

Time Range

January 2021 to December 2024

Freshness

Last updated 2026-04 15 09:55:26; freshness should be verified.

Geography

null